Can calcium sprays alleviate jelly seed in mango fruits?

Jelly seed is a major challenge in mango production leading to enormous losses in the value chain. This internal fruit disorder is characterised by disintegration of cells, consistency of jelly and broken cells. Calcium plays an important role in enhancing tissue stability and firmness thus reducing cell disintegration. A two-year field study was conducted in Embu County, Kenya using ‘Van Dyke’ cultivar trees of approximately 10 years old. The objective of the study was to investigate the effect of varied sources of calcium, applied at different rates and timing on jelly seed occurrence and tissue calcium distribution. Calcium  in the form of calcium chloride, calcium nitrate and  easygro®  were applied at 1.0%, 1.5%, 2.0% or 0% (control) at three stages of  fruit development  (fruit set, 30 days after fruit set and 30 days to anticipated physiological maturity). The experiment was set up in a randomised complete block design with a split-split arrangement replicated three times. Fruits were harvested at physiological maturity and ripened at ambient conditions (28±1̊C, 75-80 RH). Data collected included: jelly seed occurrence, calcium distribution (exocarp, mesocarp, endocarp and cotyledon) and fruit weight. Jelly seed occurrence and calcium distribution were determined at ripe stage. All the calcium sources invariably suppressed the occurrence of jelly seed. Calcium chloride (2.0%) applied at fruit set had the lowest average jelly seed score of 1.2 and 2 in seasons I and II respectively. There was a significant negative relationship between fruit weight (r = -0.55, r = -0.52), calcium content in the exocarp (r = -0.56, -0.49), mesocarp (r = -0.52,-0.76), endocarp (r= -0.76, -0.66) and jelly seed incidence occurrence. This suggested that calcium has a role in alleviating jelly seed disorder. Application of calcium at fruit set was more effective in suppressing jelly seed occurrence than later applications. Calcium chloride (2.0%) applied at fruit set was more effective in reducing jelly seed occurrence. There is need to study further on soil based calciumand other calcium formulations on the effects on jelly seed occurrence

Evaluating the Potential of Juice from Some Sweet Sorghum Varieties Grown In Kenya to Crystallize

Sweet sorghum (Sorghum bicolor (L) Moench) is a crop analogous to sugarcane with similar accumulation of sugars in its juicy stems. An earlier research study on agronomic trials carried out by Jomo Kenyatta University of Agriculture and Technology established that some of the imported varieties of Sweet Sorghum had sufficiently high amounts of sugar content in their Juice. The present study was undertaken with the objective of determining the potential of some of these sweet sorghum varieties to produce crystal sugar. This was with the long term goal of trying to find alternative uses for sweet sorghum. The sweet sorghum varieties were planted at the University research farm, and stalks of sixteen varieties were crushed using electrical roller mill to produce SS juice which was then subjected to a number of analyses including, total and specific sugar determination and apparent purity. The total sugars in degree Brix varied from 15.050 to 21.500, sucrose concentration ranged from 6.05g/l to72.77g/l, glucose 2.65g/l to 16.41g/l and fructose 2.66g/l to 17.16g/l whereas apparent purity(AP) ranged from 33.89% to 83.91%.The variation could have been  brought about by varietal differences. The juice of variety RIO had the highest sucrose purity of 83.91% which was further clarified by liming and double carbonation method. The resulting juice was concentrated into syrup by evaporation. Supersaturation for crystallization was attained by cooling, followed by seeding. According to the present study, the following sweet sorghum cultivars; Rio, CMSXS636, IESV91018LT, IESV93042SH and SPV1411 could have potential in crystal raw sugar production because they have AP greater than 75% and a relatively higher sucrose concentration. The Rio sweet sorghum variety with the highest sucrose purity of 83.91% and sucrose concentration of 40.86g/l was selected and subjected to crystal sugar production processes. The Rio juice subjected to crystallization process failed to produce crystals probably due to the presence of dextran, aconitic acid and starch. Key words: Brix, Sucrose, apparent purity, Clarification, Crystal Sugar,

The role of women’s empowerment and male engagement in pregnancy healthcare seeking behaviors in western Kenya

We sought to understand whether women’s empowerment and male partner engagement were associated with use of antenatal care (ANC). Women presenting for ANC in Nyanza province of Kenya between June 2015 and May 2016, were approached for participation. A total of 137 pregnant women and 96 male partners completed baseline assessments. Women’s empowerment was measured using the modified Sexual Relationship Power Scale. ANC use measures included timing of the first ANC visit and number of visits. Male engagement was based on whether a husband reported accompanying his wife to one or more antenatal visits during the pregnancy. Multiple linear and logistic regression analyses were used to identify factors independently related to use and timing of ANC. Women with higher mean empowerment scores were likely to have more than one ANC visit in the index pregnancy [Adjusted Odds Ratio (AOR) = 2.8, 95% Confidence Interval (CI): 1.1–7.3], but empowerment was not associated with early ANC use. Women who were more empowered were less likely to have a husband who reported attending an ANC visit with his wife (AOR = 0.1, 95% CI: 0.03–0.8). Women’s empowerment is important and may be related to ANC use and engagement of male partners in complex ways

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca